Speaking of compounds and patents, yesterday Ligand was issued a patent that covered several series of molecules that modulated RXRs. Do you know how unique or novel each class is for modulating RXR associated gene expression?:
United States Patent 5,780,676Boehm, et. al.Jul. 14, 1998
------------------------------------------------------------------------
Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
Inventors: Boehm; Marcus F. (San Diego, CA); Heyman; Richard A. (Encinitas, CA); Zhi; Lin (San Diego, CA); Hwang; Chan Kou (San Diego, CA); White; Steve (San Diego, CA); Nadzan; Alex (San Diego, CA). Assignee: Ligand Pharmaceuticals Incorporated (San Diego, CA). Appl. No.: 485,386Filed: Jun. 7, 1995
Related U.S. Application Data
Continuation of (including streamline cont.) Ser. No. 141,246, Oct. 22, 1993, which is a continuation-in-part of Ser. No. 52,050, Apr. 21, 1993, abandoned, which is a continuation-in-part of Ser. No. 27,747, Mar. 5, 1993, abandoned, which is a continuation-in-part of Ser. No. 3,223, Jan. 11, 1993, abandoned, which is a continuation-in-part of Ser. No. 944,783, Sept. 11, 1992, abandoned, which is a continuation-in-part of Ser. No. 872,707, Apr. 22, 1992, abandoned.Intl. Cl. : C07C 63/36Current U.S. Cl.: 562/490; 554/220; 554/221; 562/501Field of Search: 562/490, 501; 554/220, 221
------------------------------------------------------------------------
References Cited | [Referenced By]
------------------------------------------------------------------------
U.S. Patent Documents
2,897,237Jul., 1959Carpenter et al.3,398,121Aug., 1968Oxenrider et al.3,507,906Apr., 1970Oxenrider et al.3,639,464Feb., 1972Oxenrider et al.4,141,995Feb., 1979Saunders et al.4,539,154Sept., 1985Krebs4,548,723Oct., 1985Shippey4,833,240May, 1989Maignan et al.4,877,805Oct., 1989Kligman4,898,864Feb., 1990Maignan et al.4,981,784Jan., 1991Evans et al.5,023,341Jun., 1991Chandraratna5,023,363Jun., 1991Maignan et al.5,053,523Oct., 1991Chandraratna5,071,773Dec., 1991Evans et al.5,093,516Mar., 1992Maignan et al.5,399,586Mar., 1995Davies et al.5,466,861Nov., 1995Dawson et al.
Foreign Patent Documents
0552624Nov., 1901EP0260162Mar., 1988EP0284288Sept., 1988EP0284261Sept., 1988EP2601670Jan., 1988FR1082269Sept., 1967GB1526410Sept., 1978GB1549171Jul., 1979GB2197316May, 1988GB2228734Jun., 1990GB8500806Feb., 1985WO9306086Apr., 1993WO9311755Jun., 1993WO9412880Jun., 1994WO9417796Aug., 1994WO
Other References
Angel et al., Mol. Cell. Biol., 7:2256 (1987).
Ashwell et al., Proc. Nat'l Acad. Sci., 90:6170-74 (1993).
Berger, T.S. et al., J. Steroid Biochem. Molec. Biol., 41:733-38 (1992).
Bradley, L.M., Selected Methods in Cellular Immunology, Ch. 10.1, pp. 235-238, Mishell & Shiigi (eds.), Freeman & Co., New York (1980).
Brietman et al., Proc. Nat'l Acad. Sci., 77:2936 (1980).
Brand, N. et al., Nature, 332:850-53 (Apr. 28, 1988).
Chemical Abstracts, vol. 84, No. 15, Abstract No. 105844 (Apr. 12, 1976).
Chemical Abstracts, vol. 88, No. 20, Abstract No. 144612 (May 15, 1978).
Englert, Gerhard, Helvetica Chimica Acta, vol. 58, Fasc. 8, pp. 2367-2390 (1975).
Evans, R.M., Science, 240:889-95 (May 13, 1988).
Giguere, V. et al., Nature, 330:624-29 (Dec. 17, 1987).
Gordon et al., New England J. Med., 321:1311 (1989).
Heyman, R.A. et al., Cell, 68:397-406 (Jan. 24, 1992).
Hollenberg, S.M. et al., Cell, 55:899-906 (Dec. 2, 1988).
Ishikawa, T. et al., Mol. Endo., 4:837-44 (1990).
Isseman & Green, Nature, 347:645-49 (1990).
Jong, L. et al., J. Med. Chem., 36:2605-13 (1993).
Kliewer et al., Nature, 358:771 (1992).
Kligman, L.H. et al., J. of Invest. Derm., 73:354-58 (1979).
Ladias et al., Science, 251:561-65 (1991).
Lafyatis et al., Mol. Endocrinol., 4:973 (1990).
Lehmann, J.M. et al., Science, 258:1944-46 (1992).
Levin, A.A. et al., Nature, 355:359-61 (Jan. 23, 1992).
Loeliger, P. et al., Eur. J. Med. Chem.--Chimica Therapeutica, vol. 15, No. 1, pp. 9-15 (1980).
Mangelsdorf, D.J. et al., Nature, 345:224-29 (May 17, 1990).
Mangelsdorf, D.J. et al., Cell, 66:555-61 (Aug. 9, 1991).
Mangelsdorf, D.J. et al., Genes & Devel., 6:329-44 (1992).
Mezick, J.A. et al., J. of Invest. Derm., 83:110-13 (1984).
Miyajima et al., Nucleic Acids Research, 16:11057-74 (1988).
Mlodzik et al., Cell, 60:211-24 (1990).
Murtaugh et al., J. Biol. Chem., 258:11074 (1983).
Oro et al., Nature, 347:298-301 (1990).
Petkovich, M. et al., Nature, 330:444-50 (Dec. 3, 1987).
Rottman et al., Mol. Cell. Biol., 11:3814-20 (1991).
Rubin et al., Nature, 353:265 (1991).
Schenk, H. et al., Acta Cryst., vol. B34, pp. 505-507 (1978).
Shirvastav et al., Cancer Res., 40:4438 (1980).
Sladek et al., Genes & Development, 4:2353-65 (1990).
Umesono, K. et al., Nature, 336:262-65 (Nov. 17, 1988).
Umesono, K. & Evans, R.M., Cell, 57:1139-46 (Jun. 30, 1989).
Wang et al., Nature, 340:163-66 (1989).
Wecksler & Norman, Anal. Biochem., 92:314-23 (1979).
Widom et al., Mol. Cell. Biol., 12:3380-89 (1992).
Yang, N. et al., Proc. Natl. Acad. Sci. USA, 88:3559-63 (May 1991).
Yoshihide, et al., Chemical Abstracts, 4473Of, vol. 83, p. 72 (1975).
Yuspa, S.H. et al., Cancer Research, 43:5707-12 (Dec., 1983).
Primary Examiner: Killos; Paul J.
Attorney, Agent or Firm: Lyon & Lyon LLP
------------------------------------------------------------------------
Abstract
------------------------------------------------------------------------
Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and poiyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
23 Claims, 12 Drawing Figures |
